Hepatitis C virus RNA is 5′-capped with flavin adenine dinucleotide
Anna V. Sherwood,Lizandro R. Rivera-Rangel,Line A. Ryberg,Helena S. Larsen,Klara M. Anker,Rui Costa,Cathrine B. Vågbø,Eva Jakljevič,Long V. Pham,Carlota Fernandez-Antunez,Gabriele Indrisiunaite,Agnieszka Podolska-Charlery,Julius E. R. Grothen,Nicklas W. Langvad,Nicolas Fossat,Anna Offersgaard,Amal Al-Chaer,Louise Nielsen,Anna Kuśnierczyk,Christina Sølund,Nina Weis,Judith M. Gottwein,Kenn Holmbeck,Sandro Bottaro,Santseharay Ramirez,Jens Bukh,Troels K. H. Scheel,Jeppe Vinther
DOI: https://doi.org/10.1038/s41586-023-06301-3
IF: 64.8
2023-07-06
Nature
Abstract:RNA viruses have evolved elaborate strategies to protect their genomes, including 5′ capping. However, until now no RNA 5′ cap has been identified for hepatitis C virus 1,2 (HCV), which causes chronic infection, liver cirrhosis and cancer 3 . Here we demonstrate that the cellular metabolite flavin adenine dinucleotide (FAD) is used as a non-canonical initiating nucleotide by the viral RNA-dependent RNA polymerase, resulting in a 5′-FAD cap on the HCV RNA. The HCV FAD-capping frequency is around 75%, which is the highest observed for any RNA metabolite cap across all kingdoms of life 4,5,6,7,8 . FAD capping is conserved among HCV isolates for the replication-intermediate negative strand and partially for the positive strand. It is also observed in vivo on HCV RNA isolated from patient samples and from the liver and serum of a human liver chimeric mouse model. Furthermore, we show that 5′-FAD capping protects RNA from RIG-I mediated innate immune recognition but does not stabilize the HCV RNA. These results establish capping with cellular metabolites as a novel viral RNA-capping strategy, which could be used by other viruses and affect anti-viral treatment outcomes and persistence of infection.
multidisciplinary sciences